Tocilizumab
12
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
33%
4 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
Efficacy and Safety of Tocilizumab for TAO
Tocilizumab in Covid-19 Penumonia in Buenos Aires City
High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
A Pilot Study in Severe Patients With Takayasu Arteritis.
Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19
Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis